Longevity Health Holdings Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Janakiram Ajjarapu
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2403 Sidney Street Pittsburgh PA United States of America 15203
- IPO Date
- Sep 23, 2021
- CIK
- 0001842939
- Website
- healthxage.com
- Similar Companies
- Business
- Longevity Health Holdings Inc. engages in the development, manufacturing, and marketing of bio-aesthetic and health-related products, focusing on longevity and healthy aging. The company’s core offerings include regenerative technologies for skin and hair health, specifically the Carmell Secretome™, a plasma-derived growth factor platform, and Elevai Exosomes derived from human mesenchymal stem cells. Additionally, Longevity provides cosmetic skincare and haircare products, diagnostic testing services, and nutritional supplements aimed at improving overall health and appearance. The company actively operates in the United States with clinical and production centers in New Jersey and Pennsylvania. Founded in 2020 and headquartered in Pittsburgh, Pennsylvania, Longevity Health Holdings has recently expanded through strategic acquisitions and mergers. Notably, it acquired Carmell Therapeutics in July 2023 and Elevai Skincare in January 2025, enhancing its bio-aesthetic portfolio with advanced regenerative treatment technologies. In 2025, the company announced an all-stock merger agreement with True Health Inc., operator of THPlasma, a leading plasma collection business valued at $59 million plus a $20 million earnout. This merger aims to accelerate growth by integrating plasma-derived therapeutics into its offerings and expanding its market reach. The transaction follows the mutual termination of a planned deal with 20/20 BioLabs and represents a shift toward combining diagnostics, bio-aesthetics, and plasma therapy under a unified strategy. Longevity Health Holdings projects rapid revenue growth from an estimated $10 million in 2025 to $32 million in 2026, supported by expansion into plasma collection centers and guaranteed sales off-take agreements of $100 million annually. The company achieved cash profitability in fiscal year 2024 and is targeting further organic and acquisition-driven growth to solidify its position in the longevity and regenerative health industry. Its recent business strategy reflects a comprehensive approach to fighting chronic disease and promoting healthy aging through a combination of cosmetic, diagnostic, and plasma-related health products and services. The company’s leadership team includes Chairman and CEO Rajiv Shukla and, following the merger, will include management representatives from True Health Inc. Longevity Health Holdings continues to trade on Nasdaq under the ticker symbol XAGE. This profile outlines the company's current business scope and recent strategic developments that position it for growth in regenerative bio-aesthetics and plasma therapeutics markets in North America.
Analyzing Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP)
Head-To-Head Survey: MiniMed Group (NASDAQ:MMED) versus Longevity Health (NASDAQ:XAGE)
Head to Head Contrast: Longevity Health (NASDAQ:XAGE) & Biosig Technologies (NASDAQ:STEX)
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP) Financial Comparison
Financial Analysis: Check-Cap (NASDAQ:MBAI) & Longevity Health (NASDAQ:XAGE)
Analyzing Predictive Oncology (NASDAQ:AGPU) & Longevity Health (NASDAQ:XAGE)
Why Longevity Health Stock Is Skyrocketing Today
Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction
Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs
Longevity Health Holdings Announces Business Updates
Longevity Health Holdings, Inc. Announces Reverse Stock Split
CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY
Carmell Announces Closing of Elevai Skincare Acquisition
Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products
Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out
Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index
Carmell Announces Successful Closing of $3.0 Million Private Placement